Stocks making the biggest moves midday: Alphabet, AeroVironment, Salesforce, Apogee Therapeutics & more

Midday trading was driven by a mix of AI-related product news, M&A, and stock-specific catalysts, with standout moves including Getty Images up 115% on an OpenAI agreement and Apogee Therapeutics up 47% after AbbVie agreed to acquire it for $135.11 per share, or $10.9 billion. On the downside, Alphabet fell nearly 6% after high-profile researcher departures, AeroVironment dropped 11% on an earnings restatement, and CoreWeave lost nearly 9% following insider sales disclosures. Other notable movers included Super Micro up almost 14% on a new Nvidia-based blueprint, Visteon up 7% on upgrades, and Micron up nearly 6% after price-target hikes.

Analysis

The tape is increasingly separating “AI enablers” from “AI-disrupted” software. Capital is rotating toward picks-and-shovels exposures where monetization is tied to physical buildout and capacity constraints, while perceived middle-layer software winners are being de-rated on fear that model providers can compress application margins faster than consensus expects. That dynamic helps explain why hardware-linked names with visible infrastructure demand can rally even when broader tech sentiment is uneven, while legacy software franchises remain vulnerable to multiple compression until they can prove either proprietary data moats or workflow indispensability.

The most interesting second-order effect is that the AI capex cycle is broadening from GPUs into adjacent bottlenecks: networking, memory, cooling, power, and site development. That is bullish for suppliers with leverage to incremental rack density and buildout velocity, but it also raises the probability of short-term order pull-forwards and subsequent digestion phases. In other words, the winners here may see stronger near-term bookings but also more volatile quarters as customers front-load deployments ahead of platform transitions.

On the event-driven side, the biotech and industrial M&A prints suggest strategic buyers are still willing to pay up for scarce assets with clear portfolio fit, which should tighten the spread for similarly positioned smaller-cap targets. The headline premiums are a useful signal that quality growth with platform relevance still clears the market, but they also increase the risk that crowded “orphaned growth” names are vulnerable to being traded more as takeover optionality than as standalone fundamentals.

Key Decisions for Investors

• Long SMCI vs short CRM for a 1-3 month relative-value trade: own the name with direct AI capex exposure and short the one facing multiple compression from AI disruption fears; stop if CRM re-rates on credible AI monetization data.
• Add to MU and SNDK on any intraday weakness over the next 2-4 weeks: memory is a leveraged beneficiary of AI infrastructure breadth, and the earnings revision cycle can extend longer than the market expects; risk is a faster-than-expected digestion of server inventory.
• Buy NVDA call spreads 3-6 months out rather than outright stock: the thesis is less about one product announcement than about continued ecosystem pull-through from power, networking, and memory; capped upside is acceptable given elevated event risk.
• Fade CRWV rallies into strength over the next several sessions: insider sales do not prove deterioration, but they often cap multiple expansion when the market is already debating durability of hypergrowth; use tight risk controls because AI demand could quickly invalidate the short.
• Consider a pairs basket long APGE/ABBV and short a small-cap biotech index proxy for 3-9 months: the takeout validates strategic value in differentiated immunology/respiratory assets, but the goal is to own the specific asset with bid support rather than broad biotech beta.